哈药集团股份有限公司（以下简称"公司"）第十届董事会第 二十四次会议以书面方式发出通知，于 2026 年 3 月 9 日以通讯表 决方式召开。会议应参加董事 9 人，实际参加董事 9 人。会议召开 符合《中华人民共和国公司法》和《公司章程》的有关规定，会议 审议通过了《关于公司部分内部管理机构调整的议案》（同意 9 票， 反对 0 票，弃权 0 票）。 根据公司战略规划的总体部署，进一步加强合规体系建设，持 续优化管理架构，提升管理的规范性与有效性，经董事会研究决定， 将审计监察部分拆为审计部和市场监察部。审计部承接原审计监察 部的审计职能及人员；市场监察部承接原审计监察部的监察职能及 人员。 特此公告。 哈药集团股份有限公司董事会 证券代码：600664 证券简称：哈药股份 编号：2026-009 哈药集团股份有限公司 十届二十四次董事会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 二〇二六年三月十日 1 ...

Investment Rating - The report does not explicitly provide an investment rating for the industry Core Insights - The goji berry health food market is expected to grow significantly due to increasing health awareness, an aging population, and innovation in product development [4][9] - The market size is projected to increase from 17.247 billion RMB in 2020 to 19.620 billion RMB in 2024, with a compound annual growth rate (CAGR) of 3.27%, and further to 23.955 billion RMB by 2029, with a CAGR of 4.26% [8] - The industry is transitioning from traditional nourishment to precise health solutions, focusing on scientific validation and functional differentiation [29] - The supply chain is evolving from traditional cultivation to a comprehensive industry chain, enhancing quality and sustainability [30] - Consumer demand is diversifying, with a shift from single goji berry products to a variety of health-focused applications [11][12] Market Background - Goji berry health foods are primarily made from goji berries, known for their health benefits such as lowering blood pressure and enhancing immunity [4][5] - The market has evolved through distinct phases, starting from its inception in the late 1990s to a rapid growth phase expected to continue until 2025 [6][7] Market Status - The market is experiencing a significant transformation in supply and demand dynamics, with a shift towards integrated supply chains and diverse product offerings [10] - The demand for goji berry health foods is increasing as consumers seek natural and effective health management options [11] Market Competition - The industry is characterized by severe product homogeneity, with leading companies including China Resources Sanjiu, Tongrentang, and Harbin Pharmaceutical Group [16][17] - The report identifies ten recommended brands based on economic returns, profitability, and industry depth [13][14][15] Development Trends - The industry is moving towards high-quality development across the entire supply chain, ensuring product quality and value enhancement [30] - Consumption scenarios for goji berry health foods are expanding beyond traditional uses to include modern lifestyle applications [31]

Core Viewpoint - Harbin Pharmaceutical Group Co., Ltd. (哈药股份) is actively working to address its parent company's losses and meet dividend conditions by distributing profits from its subsidiaries, while also focusing on enhancing its market value and operational quality [2] Financial Performance - The revenue from GNC's China operations is included in Harbin Pharmaceutical's consolidated financial statements [2] - The company plans to distribute a total of 404 million yuan (approximately 40.4 million) from its subsidiaries and holding subsidiaries to the parent company for the fiscal years 2023 and 2024 [2] Governance and Management - The company has established a "Market Value Management System" and incorporated market value management into the performance evaluation of senior management [2] - The board of directors and management are committed to maintaining market value and will develop a profit distribution plan in accordance with the Company Law and Articles of Association [2] Strategic Focus - The company aims to enhance its intrinsic value by continuously focusing on its core business and improving operational quality [2] - There is a strong emphasis on protecting shareholder rights as part of the company's strategic initiatives [2]

Core Viewpoint - Recently, Harbin Pharmaceutical Group Co., Ltd. (stock code: 600664) announced that its subsidiary, Harbin Pharmaceutical Group Pharmaceutical Factory, received a "Drug Supplement Application Approval Notice" from the National Medical Products Administration for injectable Cefotaxime Sodium, which has passed the consistency evaluation of generic drug quality and efficacy [1] Group 1 - The drug is indicated for infections caused by sensitive bacteria, including lower respiratory tract infections, urogenital infections, and gynecological infections [1] - As of the announcement date, there are a total of 239 production approvals for injectable Cefotaxime Sodium in China, with 37 manufacturers having passed the consistency evaluation [1] - The domestic sales revenue for the drug is projected to be 1.55 billion yuan in 2024, with 889 million yuan expected in the first three quarters of 2025 [1] Group 2 - The company has invested approximately 8.1573 million yuan in research and development for the consistency evaluation project of this drug [1]

Core Viewpoint - Harbin Pharmaceutical Group Co., Ltd. has announced that its subsidiary, Harbin Pharmaceutical Group Pharmaceutical Factory, has received approval from the National Medical Products Administration for the injection of Cefoperazone Sodium, which has passed the consistency evaluation of quality and efficacy for generic drugs [1][2]. Group 1: Drug Information - The drug, Cefoperazone Sodium for injection, is available in two specifications: 1.0g and 0.5g [1]. - It is indicated for infections caused by sensitive bacteria, including lower respiratory tract infections, urogenital infections, gynecological infections, bacteremia/sepsis, skin and soft tissue infections, abdominal infections, bone and joint infections, and central nervous system infections [2]. - As of the announcement date, there are 239 production approvals for Cefoperazone Sodium in China, with 37 manufacturers having passed the consistency evaluation [2]. - The projected annual sales for Cefoperazone Sodium in domestic hospitals for 2024 is estimated at 1.55 billion yuan, with sales of 889 million yuan recorded in the first three quarters of 2025 [2]. - The company has invested approximately 8.16 million yuan in the research and development of this drug's consistency evaluation project [2]. Group 2: Impact on the Company - The approval of the drug through the consistency evaluation will likely lead to increased support in medical insurance payments and procurement by medical institutions, enhancing the market share and competitiveness of the product [3]. - The experience gained from this evaluation will benefit the company's future efforts in conducting similar evaluations for other products [3].

Core Viewpoint - Harbin Pharmaceutical Group Co., Ltd. (哈药股份) announced that its subsidiary, Harbin Pharmaceutical Group Pharmaceutical Factory (哈药总厂), received approval from the National Medical Products Administration for the injectable Cefoperazone Sodium, indicating successful consistency evaluation of quality and efficacy for generic drugs [1]. Group 1 - The approved injectable Cefoperazone Sodium is available in two dosages: 1.0g and 0.5g, with respective notification numbers 2026B00713 and 2026B00715 [1]. - Cefoperazone Sodium is indicated for infections caused by sensitive bacteria, including lower respiratory tract infections, urogenital infections, gynecological infections, bacteremia/sepsis, skin and soft tissue infections, abdominal infections, bone and joint infections, and central nervous system infections [1].

Core Viewpoint - Harbin Pharmaceutical Group Co., Ltd. (哈药股份) has received approval from the National Medical Products Administration for its injectable Cefoperazone Sodium, indicating a successful evaluation of the drug's quality and efficacy consistency as a generic medication [1]. Group 1 - The company’s subsidiary, Harbin Pharmaceutical Group Pharmaceutical Factory, is the entity that received the approval for the injectable Cefoperazone Sodium [1]. - The approved formulations include 1.0g and 0.5g dosages, with specific notification numbers for each [1]. - Injectable Cefoperazone Sodium is indicated for various infections caused by sensitive bacteria, including lower respiratory tract infections, urogenital infections, gynecological infections, bacteremia/sepsis, skin and soft tissue infections, abdominal infections, bone and joint infections, and central nervous system infections [1].

剂型：注射剂 规格：1.0g（按 C16H17N5O7S2计）、0.5g（按 C16H17N5O7S2计） 证券代码：600664 证券简称：哈药股份 编号：2026-008 哈药集团股份有限公司 关于所属企业药品通过仿制药一致性评价的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，哈药集团股份有限公司（以下简称"公司"）所属企业哈 药集团制药总厂（以下简称"哈药总厂"）收到国家药品监督管理局 颁发的关于注射用头孢噻肟钠的《药品补充申请批准通知书》【1.0g （按 C16H17N5O7S2 计），通知书编号：2026B00713；0.5g（按 C16H17N5O7S2计），通知书编号：2026B00715】，以上药品通过仿制 药质量和疗效一致性评价。现将有关情况公告如下： 一、药品的基本情况 药品名称：注射用头孢噻肟钠 上市许可持有人：哈药集团制药总厂 原药品批准文号：国药准字 H23020948、国药准字 H23020947 审批结论：本品通过仿制药质量和疗效一致性评价。 二、药品的相关信息 注射用头孢噻肟钠适用于 ...

Core Viewpoint - The company announced that its subsidiary, Harbin Pharmaceutical Group, received approval from the National Medical Products Administration for the injectable Cefotaxime Sodium (1.0g, 0.5g), which has passed the consistency evaluation for generic drugs [1] Group 1: Product Approval and Market Impact - The approved drug is indicated for various infections, which may enhance the company's product portfolio [1] - The projected domestic sales for 2024 are estimated at 1.55 billion yuan, with 889 million yuan expected in the first three quarters of 2025 [1] - The company has invested approximately 8.1573 million yuan in research and development for this product [1] Group 2: Competitive Position and Future Prospects - Passing the consistency evaluation is expected to help expand the drug's market share and improve competitiveness [1] - The company acknowledges that drug sales are influenced by multiple factors, indicating potential uncertainties in future performance [1]

Core Viewpoint - The company has received approval for the listing application of the chemical raw material drug, Ferric Protein Succinylate, which marks a significant advancement in its raw material drug sector and supports its integrated development strategy in raw material and formulation [1][3]. Group 1: Drug Approval Details - The chemical raw material drug approved is Ferric Protein Succinylate, with a packaging specification of 10kg/bag and registration number Y20230001210 [1]. - The approval was granted by the National Medical Products Administration, confirming that the drug meets the relevant requirements for drug registration [1]. Group 2: R&D Investment - The company has invested approximately RMB 8.34 million (about 834.23 thousand) in the research and development of the Ferric Protein Succinylate project as of the announcement date [2]. Group 3: Market Position - As of the announcement date, there are 11 companies in China with an "A" registration status for Ferric Protein Succinylate, including the company and Jichuan Pharmaceutical Group [2]. Group 4: Strategic Impact - The approval of Ferric Protein Succinylate is expected to enhance the company's control over its raw material production and enrich its product structure, aligning with its strategic goals [3].